{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Charlotte&page=26&state=North+Carolina", "query": { "state": "North Carolina", "city": "Charlotte", "page": 26 }, "page_size": 10 }, "pagination": { "page": 26, "page_size": 10, "total_count": 953, "total_pages": 96, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Charlotte&page=27&state=North+Carolina&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Charlotte&page=25&state=North+Carolina&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T20:07:56.400Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01167712", "title": "Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Ovarian Brenner Tumor", "Ovarian Clear Cell Adenocarcinofibroma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Stage IIA Fallopian Tube Cancer AJCC v6 and v7", "Stage IIA Ovarian Cancer AJCC V6 and v7", "Stage IIB Fallopian Tube Cancer AJCC v6 and v7", "Stage IIB Ovarian Cancer AJCC v6 and v7", "Stage IIC Fallopian Tube Cancer AJCC v6 and v7", "Stage IIC Ovarian Cancer AJCC v6 and v7", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v6 and v7", "Stage IIIA Primary Peritoneal Cancer AJCC v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v6 and v7", "Stage IIIB Primary Peritoneal Cancer AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v6 and v7", "Stage IIIC Primary Peritoneal Cancer AJCC v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 692, "start_date": "2010-09-27", "completion_date": "2026-07-02", "has_results": true, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-24T20:07:56.400Z", "location_count": 559, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 374 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01167712" }, { "nct_id": "NCT01626079", "title": "Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial) and COAPT CAS", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Mitral Regurgitation", "Mitral Valve Regurgitation", "Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure Subjects", "Heart Failure" ], "interventions": [ { "name": "MitraClip System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Abbott Medical Devices", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 776, "start_date": "2012-08", "completion_date": "2024-07", "has_results": true, "last_update_posted_date": "2023-11-27", "last_synced_at": "2026-10-24T20:07:56.400Z", "location_count": 81, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 65 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01626079" }, { "nct_id": "NCT01089725", "title": "Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Osteoarthritis", "Arthritis", "Pain" ], "interventions": [ { "name": "Placebo IV", "type": "BIOLOGICAL" }, { "name": "Placebo SC", "type": "BIOLOGICAL" }, { "name": "Tanezumab SC", "type": "BIOLOGICAL" }, { "name": "Tanezumab IV", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 385, "start_date": "2010-03-30", "completion_date": "2011-02-18", "has_results": true, "last_update_posted_date": "2021-05-05", "last_synced_at": "2026-10-24T20:07:56.400Z", "location_count": 91, "location_summary": "Montgomery, Alabama • Mesa, Arizona • Phoenix, Arizona + 64 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01089725" }, { "nct_id": "NCT02046096", "title": "Cook IVC Filter Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pulmonary Embolism" ], "interventions": [ { "name": "Günther Tulip® Vena Cava Filter", "type": "DEVICE" }, { "name": "Cook Celect® Vena Cava Filters", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Cook Research Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 473, "start_date": "2014-01", "completion_date": "2019-08-09", "has_results": true, "last_update_posted_date": "2022-01-20", "last_synced_at": "2026-10-24T20:07:56.400Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 18 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02046096" }, { "nct_id": "NCT00000882", "title": "Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Delavirdine mesylate", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 300, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-29", "last_synced_at": "2026-10-24T20:07:56.400Z", "location_count": 30, "location_summary": "Birmingham, Alabama • San Diego, California • San Francisco, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Jose", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000882" }, { "nct_id": "NCT07150923", "title": "Supraglottic Airway for Resuscitation Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Neonatal Resuscitation", "Delivery Room Resuscitation", "Positive Pressure Ventilation", "Infant, Newborn", "Supraglottic Airway", "Laryngeal Mask Airways", "Implementation Research" ], "interventions": [ { "name": "Enhanced Standard of Care (\"Enhanced\")", "type": "OTHER" }, { "name": "Enhanced Standard of Care (\"Enhanced-Plus\")", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Days", "maximum_age": null, "sex": "ALL", "summary": "0 Days and older" }, "enrollment_count": 36503, "start_date": "2026-01-01", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-24T20:07:56.400Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Chula Vista, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Chula Vista", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07150923" }, { "nct_id": "NCT02617589", "title": "An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Brain Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 560, "start_date": "2016-03-01", "completion_date": "2022-03-04", "has_results": true, "last_update_posted_date": "2023-03-28", "last_synced_at": "2026-10-24T20:07:56.400Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02617589" }, { "nct_id": "NCT01507545", "title": "Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "MORAb-004", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Best supportive care", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 154, "start_date": "2012-03-27", "completion_date": "2013-10-20", "has_results": true, "last_update_posted_date": "2022-05-06", "last_synced_at": "2026-10-24T20:07:56.400Z", "location_count": 67, "location_summary": "Alhambra, California • Bakersfield, California • Burbank, California + 54 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01507545" }, { "nct_id": "NCT06286670", "title": "Single Versus Dual Implant Fixation of Distal Femur Fractures", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Articular Fractures" ], "interventions": [ { "name": "Single Implant Fixation", "type": "PROCEDURE" }, { "name": "Dual Implant Fixation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 144, "start_date": "2024-09-16", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-10-24T20:07:56.400Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Macon", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06286670" }, { "nct_id": "NCT01772472", "title": "A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "trastuzumab", "type": "DRUG" }, { "name": "trastuzumab emtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1486, "start_date": "2013-04-03", "completion_date": "2024-05-23", "has_results": true, "last_update_posted_date": "2025-07-22", "last_synced_at": "2026-10-24T20:07:56.400Z", "location_count": 60, "location_summary": "Anchorage, Alaska • Long Beach, California • Orange, California + 49 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Long Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01772472" } ] }